top of page
  • Patient Education

Patient Education: Ciltacabtagene Autoleucel - Carvykti - (CART Cell Therapy) - Immunotherapy

Updated: Jan 27


CILTA CEL CART Cell therapy Multiple Myeloma


Ciltacabtagene Autoleucel ( Carvykti)


FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma


On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.


Safety and efficacy were evaluated in CARTITUDE-1 (NCT03548207), an open label, multicenter clinical trial evaluating ciltacabtagene autoleucel in 97 patients with relapsed or refractory multiple myeloma who received at least three prior lines of therapy which included a PI, an IMiD, and an anti-CD38 monoclonal antibody and who had disease progression on or after the last chemotherapy regimen; 82% had received four or more prior lines of antimyeloma therapy.


Learn more:

 

Information on Carvykti website

 

INTERNATIONAL MYELOMA FOUNDATION:


CARVYKTI (ciltacabtagene autoleucel)


IMF Understanding Series


IMF Resource Library


Current FDA-Approved Medications for Multiple Myeloma Treatment

 

HEALTH TREE UNIVERSITY MYELOMA:


Janssen's Cilta-Cel CAR T Receives FDA Approval for Relapsed Multiple Myeloma


HealthTree University for Multiple Myeloma Lectures


Health Tree University Myeloma Videos

 

MULTIPLE MYELOMA RESERACH FOUNDATION:


Standard Treatments - BCMA-directed personalized immunotherapy - ciltacabtagene autoleucel or cilta-cel - Carvykti


MMRF Education Programs


MMRF Videos

 

References CARVYKTI- ciltacabtagene autoleucel injection, suspension:


FDA Label Prescribing Information (Revised 03/2022)



Drug Label Information at DAILYMED - NIH-National Library of Medicine


Other Resources

 


- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -

* Belantamab mafodotin (Withdrawn from United States market)

Comments


Posts Archive
bottom of page